Company intelligence / Profile preview

Imuno App

Leiden, South Holland, Netherlands

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

Imuno develops precision immunotherapies for cancer using AI-driven and synthetic biology approaches to create best-in-class TCR-mimic antibodies. The company focuses on hard-to-treat diseases, aiming to deliver potent and safe therapies for patients lacking treatment options. No published clinical results are available yet.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyTCR-mimic antibody
Industry: Biotech

Beyond the preview

Go deeper on Imuno App.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imuno App.

Explore the full profile